Moroctocog alfa
Clinical data | |
---|---|
Trade names | ReFacto, ReFacto AF |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | Intravenous (IV) |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL |
Moroctocog alfa (trade name ReFacto in the EU) is a recombinant
The most common side effects include headache, cough, pain in the joints and fever.[6] People may also develop antibodies against factor VIII medicines such as moroctocog alfa.[6] These are known as inhibitors as they can prevent the medicine from working effectively, which may result in a loss of bleeding control.[6] Uncommonly, people may also develop allergic reactions.[6]
People with haemophilia A lack factor VIII, a protein needed for normal clotting of the blood, and as a result, they bleed readily and may have problems, such as bleeding in the joints, muscles and internal organs.[6] Moroctocog alfa works in the body in the same way as human factor VIII.[6] It replaces the missing factor VIII, thereby helping the blood to clot and giving temporary control of bleeding.[6]
The human coagulation factor VIII in moroctocog alfa is not extracted from human blood but is produced by a method known as 'recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes it able to produce human coagulation factor VIII.[6]
Medical uses
Moroctocog alfa is indicated for the treatment and prophylaxis of bleeding in people with haemophilia A (congenital factor-VIII deficiency).[6] It is appropriate for use in adults and children of all ages, including newborns.[6] It does not contain von-Willebrand factor, and hence is not indicated in von-Willebrand's disease.[6]
History
Moroctocog alfa was approved for medical use in the European Union in April 1999, and sold under the brand name Refacto.[6] In February 2009, a number of changes to the way ReFacto is made were introduced.[6] These included removal of the use of a protein called albumin, which is produced from human blood, from the manufacturing process.[6] The name of the medicine was also changed from ReFacto to ReFacto AF.[6]
References
- ^ a b "Antihemophilic factor Use During Pregnancy". Drugs.com. 20 January 2020. Retrieved 11 March 2020.
- ^ "ReFacto AF 250 IU powder and solvent for solution for injection - Summary of Product Characteristics (SmPC)". (emc). 17 October 2019. Retrieved 13 May 2020.
- ^ "ReFacto sAntihemophilic Factor, Recombinant" (PDF). Wyeth Pharmaceuticals Inc.
- S2CID 28322.
- ^ "ReFacto AF 2000 IU powder and solvent for solution for injection" (PDF). Wyeth Farma S.A. European Medicines Agency.
- ^ a b c d e f g h i j k l m n o "ReFacto AF EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 13 May 2020. This article incorporates text from this source, which is in the public domain.
External links
- "Moroctocog alfa". Drug Information Portal. U.S. National Library of Medicine.